Anthony M Villano1, Roberto J Vidri2, Elaine T Vo2, Stephanie H Greco2, Krisha J Howell3, Margaret von Mehren4, Jeffrey M Farma2. 1. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. anthony.villano@fccc.edu. 2. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 3. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 4. Department of Hematology and Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Abstract
BACKGROUND: Little level 1 evidence exists to guide multimodality treatment in retroperitoneal soft tissue sarcoma (RPS), which may lead to significant variation in therapeutic approaches. This analysis aimed to describe national RPS treatment trends and explore potential variability among low-/high-volume hospitals (LVH/HVHs). PATIENTS AND METHODS: In total, 5992 patients who underwent resection for primary RPS were retrospectively identified in the National Cancer Database (2004-2017). Time trend analyses examined rates of multivisceral resection (MVR), radiation, and chemotherapy use. LVHs were defined as those carrying out fewer than ten resections per year (N = 5433), whereas HVHs were defined as those carrying out ten or more (N = 559). Descriptive statistics and logistic regression models compared trends between groups. RESULTS: MVR was more frequent at HVHs (63.7% versus 43.5%, p < 0.001). Use of radiation varied widely by hospital volume. HVHs more frequently employed preoperative radiation as compared with LVHs (14.7% versus 8.1%, p < 0.001). Throughout the study period, LVHs increased utilization of preoperative radiation (2.6% to 12.0%, p < 0.001) whereas rates at HVHs remained stable. Overall, LVHs utilized postoperative radiation significantly more frequently as compared with HVHs (14.7% versus 2.7%, respectively, p < 0.001). Postoperative radiation at LVHs remained stable until 2013 and sharply declined thereafter (16.7% to 6.9%, p < 0.001). Rates of postoperative radiation use at HVHs remained lower than those at LVHs at all time points. CONCLUSIONS: Strategies for resection and radiation use at LVHs have trended towards those of HVHs. Current national implementation of preoperative radiation, MVR, and chemotherapy remains heterogeneous. These findings inform future trial design and support standardization of care.
BACKGROUND: Little level 1 evidence exists to guide multimodality treatment in retroperitoneal soft tissue sarcoma (RPS), which may lead to significant variation in therapeutic approaches. This analysis aimed to describe national RPS treatment trends and explore potential variability among low-/high-volume hospitals (LVH/HVHs). PATIENTS AND METHODS: In total, 5992 patients who underwent resection for primary RPS were retrospectively identified in the National Cancer Database (2004-2017). Time trend analyses examined rates of multivisceral resection (MVR), radiation, and chemotherapy use. LVHs were defined as those carrying out fewer than ten resections per year (N = 5433), whereas HVHs were defined as those carrying out ten or more (N = 559). Descriptive statistics and logistic regression models compared trends between groups. RESULTS: MVR was more frequent at HVHs (63.7% versus 43.5%, p < 0.001). Use of radiation varied widely by hospital volume. HVHs more frequently employed preoperative radiation as compared with LVHs (14.7% versus 8.1%, p < 0.001). Throughout the study period, LVHs increased utilization of preoperative radiation (2.6% to 12.0%, p < 0.001) whereas rates at HVHs remained stable. Overall, LVHs utilized postoperative radiation significantly more frequently as compared with HVHs (14.7% versus 2.7%, respectively, p < 0.001). Postoperative radiation at LVHs remained stable until 2013 and sharply declined thereafter (16.7% to 6.9%, p < 0.001). Rates of postoperative radiation use at HVHs remained lower than those at LVHs at all time points. CONCLUSIONS: Strategies for resection and radiation use at LVHs have trended towards those of HVHs. Current national implementation of preoperative radiation, MVR, and chemotherapy remains heterogeneous. These findings inform future trial design and support standardization of care.
Authors: Rolf D Issels; Lars H Lindner; Jaap Verweij; Peter Wust; Peter Reichardt; Baard-Christian Schem; Sultan Abdel-Rahman; Soeren Daugaard; Christoph Salat; Clemens-Martin Wendtner; Zeljko Vujaskovic; Rüdiger Wessalowski; Karl-Walter Jauch; Hans Roland Dürr; Ferdinand Ploner; Andrea Baur-Melnyk; Ulrich Mansmann; Wolfgang Hiddemann; Jean-Yves Blay; Peter Hohenberger Journal: Lancet Oncol Date: 2010-04-29 Impact factor: 41.316
Authors: George Molina; Melissa A Hull; Yen-Lin Chen; Thomas F DeLaney; Karen De Amorim Bernstein; Edwin Choy; Gregory Cote; David C Harmon; John T Mullen; Alex B Haynes Journal: J Surg Oncol Date: 2016-09-16 Impact factor: 3.454
Authors: Sean M McBride; Chandrajit P Raut; Michelle Lapidus; Phillip M Devlin; Karen J Marcus; Monica Bertagnolli; Suzanne George; Elizabeth H Baldini Journal: Ann Surg Oncol Date: 2013-02-08 Impact factor: 5.344
Authors: Robert A Zlotecki; Teri S Katz; Christopher G Morris; D Scott Lind; Steven N Hochwald Journal: Am J Clin Oncol Date: 2005-06 Impact factor: 2.339
Authors: Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Brian R Englum; David G Kirsch; Douglas S Tyler; Dan G Blazer Journal: Ann Surg Date: 2015-07 Impact factor: 12.969
Authors: William W Tseng; Francesco Barretta; Lorenzo Conti; Giovanni Grignani; Francesco Tolomeo; Markus Albertsmeier; Martin K Angele; Piotr Rutkowski; Jacek Skoczylas; Antonino De Paoli; Federico Navarria; Chandrajit P Raut; Mark Fairweather; Jeffrey M Farma; Carolyn Nessim; Neha Goel; Valerie P Grignol; Samuel J Ford; Kenneth Cardona; Ty Subhawong; Hannah L Tattersall; Rachel M Lee; James S Hu; Margaret von Mehren; Roberta Sanfilippo; Alessandro Gronchi Journal: Cancer Date: 2020-11-18 Impact factor: 6.860
Authors: J T Miura; J Charlson; T C Gamblin; D Eastwood; A Banerjee; F M Johnston; K K Turaga Journal: Eur J Surg Oncol Date: 2015-07-29 Impact factor: 4.424
Authors: B L Ecker; M G Peters; M T McMillan; A J Sinnamon; P J Zhang; D L Fraker; W P Levin; R E Roses; G C Karakousis Journal: Br J Surg Date: 2016-09-29 Impact factor: 6.939
Authors: Sanjay P Bagaria; Matthew Neville; Richard J Gray; Emmanuel Gabriel; Jonathan B Ashman; Steven Attia; Nabil Wasif Journal: Sarcoma Date: 2018-07-24
Authors: Sung Jun Ma; Oluwadamilola T Oladeru; Mark K Farrugia; Rohil Shekher; Austin J Iovoli; Anurag K Singh Journal: JAMA Netw Open Date: 2020-11-02